Options and obstacles for designing a universal influenza vaccine

Viruses

Volumn 6, Issue 8, 2014, Pages 3159-3180

  Jang, Yo Han ^a   Seong, Baik Lin ^a  

^a Yonsei University   (South Korea)

Author keywords

Cross protection; Hemagglutinin; Influenza virus; Live vaccine; Universal vaccine

Indexed keywords

CHIMERIC PROTEIN; EPITOPE; HEMAGGLUTININ; INFLUENZA VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; INFLUENZA VIRUS HEMAGGLUTININ; VIRUS ANTIBODY;

AMINO ACID SEQUENCE; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; CROSS REACTION; CRYSTALLOGRAPHY; DRUG ANTIGENICITY; DRUG DESIGN; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA A; INFLUENZA B; NONHUMAN; PHYLOGENETIC TREE; PROTEIN CLEAVAGE; PROTEIN GLYCOSYLATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS INHIBITION; REVIEW; VACCINATION; VIRUS GENOME; VIRUS INFECTION; VIRUS INHIBITION; BLOOD; CROSS PROTECTION; DRUG DEVELOPMENT; GENETICS; IMMUNOLOGY; INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; NUCLEOTIDE SEQUENCE; PROCEDURES; TRENDS;

ANTIBODIES, VIRAL; CONSERVED SEQUENCE; CROSS PROTECTION; CROSS REACTIONS; DRUG DISCOVERY; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN;

EID: 84925883384     PISSN: 19994915     EISSN: None     Source Type: Journal    
DOI: 10.3390/v6083159     Document Type: Review

References (114)

1. Glezen, W.P. Clinical practice. Prevention and treatment of seasonal influenza. N. Engl. J. Med. 2008, 359, 2579-2585.
2. Thijs, C.; Knottnerus, A. Influenza vaccination and risk of community-acquired pneumonia. Lancet 2008, 372, 2112-2113.
3. Ohmit, S.E.; Gross, J.; Victor, J.C.; Monto, A.S. Reduced reaction frequencies with repeated inactivated or live-attenuated influenza vaccination. Vaccine 2009, 27, 1050-1054.
4. Potter, C.W. A history of influenza. J. Appl. Microbiol. 2001, 91, 572-579.
5. Yewdell, J.W.; Webster, R.G.; Gerhard, W.U. Antigenic variation in three distinct determinants of an influenza type A haemagglutinin molecule. Nature 1979, 279, 246-248.
6. Gerdil, C. The annual production cycle for influenza vaccine. Vaccine 2003, 21, 1776-1779.
7. Klimov, A.; Simonsen, L.; Fukuda, K.; Cox, N. Surveillance and impact of influenza in the United States. Vaccine 1999, 17, S42-S46.
8. Bridges, C.B.; Thompson, W.W.; Meltzer, M.I.; Reeve, G.R.; Talamonti, W.J.; Cox, N.J.; Lilac, H.A.; Hall, H.; Klimov, A.; Fukuda, K. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. JAMA 2000, 284, 1655-1663.
9. Gao, R.; Cao, B.; Hu, Y.; Feng, Z.; Wang, D.; Hu, W.; Chen, J.; Jie, Z.; Qiu, H.; Xu, K.; et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N. Engl. J. Med. 2013, 368, 1888-1897.
10. Baz, M.; Paskel, M.; Matsuoka, Y.; Zengel, J.; Cheng, X.; Jin, H.; Subbarao, K. Replication and immunogenicity of swine, equine, and avian h3 subtype influenza viruses in mice and ferrets. J. Virol. 2013, 87, 6901-6910.
11. Fiers, W.; de Filette, M.; El Bakkouri, K.; Schepens, B.; Roose, K.; Schotsaert, M.; Birkett, A.; Saelens, X. M2e-based universal influenza A vaccine. Vaccine 2009, 27, 6280-6283.
12. Pica, N.; Palese, P. Toward a universal influenza virus vaccine: Prospects and challenges. Annu. Rev. Med. 2013, 64, 189-202.
13. Subbarao, K.; Matsuoka, Y. The prospects and challenges of universal vaccines for influenza. Trends Microbiol. 2013, 21, 350-358.
14. Bullough, P.A.; Hughson, F.M.; Skehel, J.J.; Wiley, D.C. Structure of influenza haemagglutinin at the pH of membrane fusion. Nature 1994, 371, 37-43.
15. Skehel, J.J.; Bayley, P.M.; Brown, E.B.; Martin, S.R.; Waterfield, M.D.; White, J.M.; Wilson, I.A.; Wiley, D.C. Changes in the conformation of influenza virus hemagglutinin at the pH optimum of virus-mediated membrane fusion. Proc. Natl. Acad. Sci. USA 1982, 79, 968-972.
16. Tong, S.; Zhu, X.; Li, Y.; Shi, M.; Zhang, J.; Bourgeois, M.; Yang, H.; Chen, X.; Recuenco, S.; Gomez, J.; et al. New world bats harbor diverse influenza A viruses. PLoS Pathog. 2013, 9, e1003657.
17. Fouchier, R.A.M.; Munster, V.; Wallensten, A.; Bestebroer, T.M.; Herfst, S.; Smith, D.; Rimmelzwaan, G.F.; Olsen, B.; Osterhaus, A.D.M.E. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J. Virol. 2005, 79, 2814-2822.
18. Russell, R.J.; Kerry, P.S.; Stevens, D.J.; Steinhauer, D.A.; Martin, S.R.; Gamblin, S.J.; Skehel, J.J. Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc. Natl. Acad. Sci. USA 2008, 105, 17736-17741.
19. Ekiert, D.C.; Bhabha, G.; Elsliger, M.A.; Friesen, R.H.; Jongeneelen, M.; Throsby, M.; Goudsmit, J.; Wilson, I.A. Antibody recognition of a highly conserved influenza virus epitope. Science 2009, 324, 246-251.
20. Xu, R.; Ekiert, D.C.; Krause, J.C.; Hai, R.; Crowe, J.E., Jr.; Wilson, I.A. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 2010, 328, 357-360.
21. Krystal, M.; Elliott, R.M.; Benz, E.W., Jr.; Young, J.F.; Palese, P. Evolution of influenza A and B viruses: Conservation of structural features in the hemagglutinin genes. Proc. Natl. Acad. Sci. USA 1982, 79, 4800-4804.
22. Sui, J.; Sheehan, J.; Hwang, W.C.; Bankston, L.A.; Burchett, S.K.; Huang, C.Y.; Liddington, R.C.; Beigel, J.H.; Marasco, W.A. Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Clin. Infect. Dis. 2011, 52, 1003-1009.
23. Corti, D.; Suguitan, A.L., Jr.; Pinna, D.; Silacci, C.; Fernandez-Rodriguez, B.M.; Vanzetta, F.; Santos, C.; Luke, C.J.; Torres-Velez, F.J.; Temperton, N.J.; et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Investig. 2010, 120, 1663-1673.
24. Okuno, Y.; Isegawa, Y.; Sasao, F.; Ueda, S. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J. Virol. 1993, 67, 2552-2558.
25. Kashyap, A.K.; Steel, J.; Oner, A.F.; Dillon, M.A.; Swale, R.E.; Wall, K.M.; Perry, K.J.; Faynboym, A.; Ilhan, M.; Horowitz, M.; et al. Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc. Natl. Acad. Sci. USA 2008, 105, 5986-5991.
26. Kashyap, A.K.; Steel, J.; Rubrum, A.; Estelles, A.; Briante, R.; Ilyushina, N.A.; Xu, L.; Swale, R.E.; Faynboym, A.M.; Foreman, P.K.; et al. Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor-based libraries. PLoS Pathog. 2010, 6, e1000990.
27. Throsby, M.; van den Brink, E.; Jongeneelen, M.; Poon, L.L.M.; Alard, P.; Cornelissen, L.; Bakker, A.; Cox, F.; van Deventer, E.; Guan, Y.; et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 2008, 3, e3942.
28. Sui, J.; Hwang, W.C.; Perez, S.; Wei, G.; Aird, D.; Chen, L.M.; Santelli, E.; Stec, B.; Cadwell, G.; Ali, M.; et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 2009, 16, 265-273.
29. Nobusawa, E.; Aoyama, T.; Kato, H.; Suzuki, Y.; Tateno, Y.; Nakajima, K. Comparison of complete amino acid sequences and receptor-binding properties among 13 serotypes of hemagglutinins of influenza A viruses. Virology 1991, 182, 475-485.
30. Webster, R.G.; Bean, W.J.; Gorman, O.T.; Chambers, T.M.; Kawaoka, Y. Evolution and ecology of influenza A viruses. Microbiol. Rev. 1992, 56, 152-179.
31. Ekiert, D.C.; Friesen, R.H.; Bhabha, G.; Kwaks, T.; Jongeneelen, M.; Yu, W.; Ophorst, C.; Cox, F.; Korse, H.J.; Brandenburg, B.; et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 2011, 333, 843-850.
32. Friesen, R.H.; Lee, P.S.; Stoop, E.J.; Hoffman, R.M.; Ekiert, D.C.; Bhabha, G.; Yu, W.; Juraszek, J.; Koudstaal, W.; Jongeneelen, M.; et al. A common solution to group 2 influenza virus neutralization. Proc. Natl. Acad. Sci. USA 2014, 111, 445-450.
33. Corti, D.; Voss, J.; Gamblin, S.J.; Codoni, G.; Macagno, A.; Jarrossay, D.; Vachieri, S.G.; Pinna, D.; Minola, A.; Vanzetta, F.; et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011, 333, 850-856.
34. Dreyfus, C.; Laursen, N.S.; Kwaks, T.; Zuijdgeest, D.; Khayat, R.; Ekiert, D.C.; Lee, J.H.; Metlagel, Z.; Bujny, M.V.; Jongeneelen, M.; et al. Highly conserved protective epitopes on influenza B viruses. Science 2012, 337, 1343-1348.
35. Jegerlehner, A.; Schmitz, N.; Storni, T.; Bachmann, M.F. Influenza A vaccine based on the extracellular domain of M2: Weak protection mediated via antibody-dependent NK cell activity. J. Immunol. 2004, 172, 5598-5605.
36. Mozdzanowska, K.; Maiese, K.; Furchner, M.; Gerhard, W. Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection. Virology 1999, 254, 138-146.
37. Huber, V.C.; Lynch, J.M.; Bucher, D.J.; Le, J.; Metzger, D.W. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J. Immunol. 2001, 166, 7381-7388.
38. Zebedee, S.L.; Lamb, R.A. Influenza A virus M2 protein: Monoclonal antibody restriction of virus growth and detection of M2 in virions. J. Virol. 1988, 62, 2762-2772.
39. Dilillo, D.J.; Tan, G.S.; Palese, P.; Ravetch, J.V. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat. Med. 2014, 20, 143-151.
40. Whittle, J.R.R.; Zhang, R.; Khurana, S.; King, L.R.; Manischewitz, J.; Golding, H.; Dormitzer, P.R.; Haynes, B.F.; Walter, E.B.; Moody, M.A.; et al. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc. Natl. Acad. Sci. USA 2011, 108, 14216-14221.
41. Krause, J.C.; Tsibane, T.; Tumpey, T.M.; Huffman, C.J.; Basler, C.F.; Crowe, J.E., Jr. A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. J. Virol. 2011, 85, 10905-10908.
42. Ekiert, D.C.; Kashyap, A.K.; Steel, J.; Rubrum, A.; Bhabha, G.; Khayat, R.; Lee, J.H.; Dillon, M.A.; O'Neil, R.E.; Faynboym, A.M.; et al. Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature 2012, 489, 526-532.
43. Wei, C.J.; Boyington, J.C.; McTamney, P.M.; Kong, W.P.; Pearce, M.B.; Xu, L.; Andersen, H.; Rao, S.; Tumpey, T.M.; Yang, Z.Y.; et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 2010, 329, 1060-1064.
44. Wei, C.J.; Yassine, H.M.; McTamney, P.M.; Gall, J.G.; Whittle, J.R.; Boyington, J.C.; Nabel, G.J. Elicitation of broadly neutralizing influenza antibodies in animals with previous influenza exposure. Sci. Transl. Med. 2012, 4, 147ra114.
45. Miller, M.S.; Gardner, T.J.; Krammer, F.; Aguado, L.C.; Tortorella, D.; Basler, C.F.; Palese, P. Neutralizing antibodies against previously encountered influenza virus strains increase over time: A longitudinal analysis. Sci. Transl. Med. 2013, 5, 198ra107.
46. Wrammert, J.; Koutsonanos, D.; Li, G.M.; Edupuganti, S.; Sui, J.; Morrissey, M.; McCausland, M.; Skountzou, I.; Hornig, M.; Lipkin, W.I.; et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 2011, 208, 181-193.
47. Pica, N.; Hai, R.; Krammer, F.; Wang, T.T.; Maamary, J.; Eggink, D.; Tan, G.S.; Krause, J.C.; Moran, T.; Stein, C.R.; et al. Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc. Natl. Acad. Sci. USA 2012, 109, 2573-2578.
48. Krammer, F.; Pica, N.; Hai, R.; Tan, G.S.; Palese, P. Hemagglutinin stalk-reactive antibodies are boosted following sequential infection with seasonal and pandemic H1N1 influenza virus in mice. J. Virol. 2012, 86, 10302-10307.
49. Miller, M.S.; Tsibane, T.; Krammer, F.; Hai, R.; Rahmat, S.; Basler, C.F.; Palese, P. 1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans. J. Infect. Dis. 2013, 207, 98-105.
50. Margine, I.; Hai, R.; Albrecht, R.A.; Obermoser, G.; Harrod, A.C.; Banchereau, J.; Palucka, K.; Garcia-Sastre, A.; Palese, P.; Treanor, J.J.; et al. H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice. J. Virol. 2013, 87, 4728-4737.
51. Krammer, F.; Pica, N.; Hai, R.; Margine, I.; Palese, P. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J. Virol. 2013, 87, 6542-6550.
52. Margine, I.; Krammer, F.; Hai, R.; Heaton, N.S.; Tan, G.S.; Andrews, S.A.; Runstadler, J.A.; Wilson, P.C.; Albrecht, R.A.; Garcia-Sastre, A.; et al. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. J. Virol. 2013, 87, 10435-10446.
53. Krammer, F.; Margine, I.; Hai, R.; Flood, A.; Hirsh, A.; Tsvetnitsky, V.; Chen, D.; Palese, P. H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge. J. Virol. 2014, 88, 2340-2343.
54. Krammer, F.; Hai, R.; Yondola, M.; Tan, G.S.; Leyva-Grado, V.H.; Ryder, A.B.; Miller, M.S.; Rose, J.K.; Palese, P.; Garcia-Sastre, A.; et al. Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets. J. Virol. 2014, 88, 3432-3442.
55. Lu, Y.; Welsh, J.P.; Swartz, J.R. Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines. Proc. Natl. Acad. Sci. USA 2014, 111, 125-130.
56. Jang, Y.H.; Cho, S.H.; Son, A.; Lee, Y.H.; Lee, J.; Lee, K.H.; Seong, B.L. High-yield soluble expression of recombinant influenza virus antigens from Escherichia coli and their potential uses in diagnosis. J. Virol. Methods 2014, 196, 56-64.
57. Hoffmann, E.; Neumann, G.; Kawaoka, Y.; Hobom, G.; Webster, R.G. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc. Natl. Acad. Sci. USA 2000, 97, 6108-6113.
58. Schulze, I.T. Effects of glycosylation on the properties and functions of influenza virus hemagglutinin. J. Infect. Dis. 1997, 176, S24-S28.
59. Skehel, J.J.; Stevens, D.J.; Daniels, R.S.; Douglas, A.R.; Knossow, M.; Wilson, I.A.; Wiley, D.C. A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by a monoclonal antibody. Proc. Natl. Acad. Sci. USA 1984, 81, 1779-1783.
60. Medina, R.A.; Stertz, S.; Manicassamy, B.; Zimmermann, P.; Sun, X.; Albrecht, R.A.; Uusi-Kerttula, H.; Zagordi, O.; Belshe, R.B.; Frey, S.E.; et al. Glycosylations in the globular head of the hemagglutinin protein modulate the virulence and antigenic properties of the H1N1 influenza viruses. Sci. Transl. Med. 2013, 5, 187ra170.
61. Kim, J.I.; Lee, I.; Park, S.; Hwang, M.W.; Bae, J.Y.; Lee, S.; Heo, J.; Park, M.S.; Garcia-Sastre, A.; Park, M.S. Genetic requirement for hemagglutinin glycosylation and its implications for influenza A H1N1 virus evolution. J. Virol. 2013, 87, 7539-7549.
62. Sun, X.; Jayaraman, A.; Maniprasad, P.; Raman, R.; Houser, K.V.; Pappas, C.; Zeng, H.; Sasisekharan, R.; Katz, J.M.; Tumpey, T.M. N-linked glycosylation of the hemagglutinin protein influences virulence and antigenicity of the 1918 pandemic and seasonal H1N1 influenza A viruses. J. Virol. 2013, 87, 8756-8766.
63. Das, S.R.; Puigbo, P.; Hensley, S.E.; Hurt, D.E.; Bennink, J.R.; Yewdell, J.W. Glycosylation focuses sequence variation in the influenza A virus H1 hemagglutinin globular domain. PLoS Pathog. 2010, 6, e1001211.
64. Eggink, D.; Goff, P.H.; Palese, P. Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain. J. Virol. 2014, 88, 699-704.
65. Cohen, M.S.; Hellmann, N.; Levy, J.A.; DeCock, K.; Lange, J. The spread, treatment, and prevention of HIV-1: Evolution of a global pandemic. J. Clin. Investig. 2008, 118, 1244-1254.
66. VandeWoude, S.; Apetrei, C. Going wild: Lessons from naturally occurring T-lymphotropic lentiviruses. Clin. Microbiol. Rev. 2006, 19, 728-762.
67. Huisman, W.; Martina, B.E.; Rimmelzwaan, G.F.; Gruters, R.A.; Osterhaus, A.D. Vaccine-induced enhancement of viral infections. Vaccine 2009, 27, 505-512.
68. Kim, H.W.; Bellanti, J.A.; Arrobio, J.O.; Mills, J.; Brandt, C.D.; Chanock, R.M.; Parrott, R.H. Respiratory syncytial virus neutralizing activity in nasal secretions following natural infection. Proc. Soc. Exp. Biol. Med. 1969, 131, 658-661.
69. Polack, F.P.; Teng, M.N.; Collins, P.L.; Prince, G.A.; Exner, M.; Regele, H.; Lirman, D.D.; Rabold, R.; Hoffman, S.J.; Karp, C.L.; et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J. Exp. Med. 2002, 196, 859-865.
70. Fulginiti, V.A.; Eller, J.J.; Downie, A.W.; Kempe, C.H. Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA 1967, 202, 1075-1080.
71. Vincent, A.L.; Lager, K.M.; Janke, B.H.; Gramer, M.R.; Richt, J.A. Failure of protection and enhanced pneumonia with a US H1N2 swine influenza virus in pigs vaccinated with an inactivated classical swine H1N1 vaccine. Vet. Microbiol. 2008, 126, 310-323.
72. Gauger, P.C.; Vincent, A.L.; Loving, C.L.; Lager, K.M.; Janke, B.H.; Kehrli, M.E., Jr.; Roth, J.A. Enhanced pneumonia and disease in pigs vaccinated with an inactivated human-like (delta-cluster) H1N2 vaccine and challenged with pandemic 2009 H1N1 influenza virus. Vaccine 2011, 29, 2712-2719.
73. Gauger, P.C.; Vincent, A.L.; Loving, C.L.; Henningson, J.N.; Lager, K.M.; Janke, B.H.; Kehrli, M.E., Jr.; Roth, J.A. Kinetics of lung lesion development and pro-inflammatory cytokine response in pigs with vaccine-associated enhanced respiratory disease induced by challenge with pandemic (2009) A/H1N1 influenza virus. Vet. Pathol. 2012, 49, 900-912.
74. Khurana, S.; Loving, C.L.; Manischewitz, J.; King, L.R.; Gauger, P.C.; Henningson, J.; Vincent, A.L.; Golding, H. Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease. Sci. Transl. Med. 2013, 5, 200ra114.
75. Janjua, N.Z.; Skowronski, D.M.; Hottes, T.S.; Osei, W.; Adams, E.; Petric, M.; Sabaiduc, S.; Chan, T.; Mak, A.; Lem, M.; et al. Seasonal influenza vaccine and increased risk of pandemic A/H1N1-related illness: First detection of the association in British Columbia, Canada. Clin. Infect. Dis. 2010, 51, 1017-1027.
76. Skowronski, D.M.; De Serres, G.; Crowcroft, N.S.; Janjua, N.Z.; Boulianne, N.; Hottes, T.S.; Rosella, L.C.; Dickinson, J.A.; Gilca, R.; Sethi, P.; et al. Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: Four observational studies from Canada. PLoS Med. 2010, 7, e1000258.
77. To, K.K.; Zhang, A.J.; Hung, I.F.; Xu, T.; Ip, W.C.; Wong, R.T.; Ng, J.C.; Chan, J.F.; Chan, K.H.; Yuen, K.Y. High titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza. Clin. Vaccine Immunol. 2012, 19, 1012-1018.
78. Cowling, B.J.; Ng, S.; Ma, E.S.; Fang, V.J.; So, H.C.; Wai, W.; Cheng, C.K.; Wong, J.Y.; Chan, K.H.; Ip, D.K.; et al. Protective efficacy against pandemic influenza of seasonal influenza vaccination in children in Hong Kong: A randomized controlled trial. Clin. Infect. Dis. 2012, 55, 695-702.
79. Johns, M.C.; Eick, A.A.; Blazes, D.L.; Lee, S.-E.; Perdue, C.L.; Lipnick, R.; Vest, K.G.; Russell, K.L.; DeFraites, R.F.; Sanchez, J.L. Seasonal influenza vaccine and protection against pandemic (H1N1) 2009-associated illness among US military personnel. PLoS One 2010, 5, e10722.
80. Garcia-Garcia, L.; Valdespino-Gómez, J.L.; Lazcano-Ponce, E.; Jimenez-Corona, A.; Higuera-Iglesias, A.; Cruz-Hervert, P.; Cano-Arellano, B.; Garcia-Anaya, A.; Ferreira-Guerrero, E.; Baez-Saldaña, R.; et al. Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: Case-control study in Mexico City. BMJ 2009, 339, b3928.
81. Heinen, P.P.; Rijsewijk, F.A.; de Boer-Luijtze, E.A.; Bianchi, A.T. Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. J. Gen. Virol. 2002, 83, 1851-1859.
82. Braucher, D.R.; Henningson, J.N.; Loving, C.L.; Vincent, A.L.; Kim, E.; Steitz, J.; Gambotto, A.A.; Kehrli, M.E., Jr. Intranasal vaccination with replication-defective adenovirus type 5 encoding influenza virus hemagglutinin elicits protective immunity to homologous challenge and partial protection to heterologous challenge in pigs. Clin. Vaccine Immunol. 2012, 19, 1722-1729.
83. Brandenburg, B.; Koudstaal, W.; Goudsmit, J.; Klaren, V.; Tang, C.; Bujny, M.V.; Korse, H.J.; Kwaks, T.; Otterstrom, J.J.; Juraszek, J.; et al. Mechanisms of hemagglutinin targeted influenza virus neutralization. PLoS One 2013, 8, e80034.
84. Bottcher, C.; Ludwig, K.; Herrmann, A.; van Heel, M.; Stark, H. Structure of influenza haemagglutinin at neutral and at fusogenic pH by electron cryo-microscopy. FEBS Lett. 1999, 463, 255-259.
85. Harris, A.K.; Meyerson, J.R.; Matsuoka, Y.; Kuybeda, O.; Moran, A.; Bliss, D.; Das, S.R.; Yewdell, J.W.; Sapiro, G.; Subbarao, K.; et al. Structure and accessibility of HA trimers on intact 2009 H1N1 pandemic influenza virus to stem region-specific neutralizing antibodies. Proc. Natl. Acad. Sci. USA 2013, 110, 4592-4597.
86. Halstead, S.B.; O'Rourke, E.J.; Allison, A.C. Dengue viruses and mononuclear phagocytes. II. Identity of blood and tissue leukocytes supporting in vitro infection. J. Exp. Med. 1977, 146, 218-229.
87. Peiris, J.S.; Porterfield, J.S. Antibody-mediated enhancement of Flavivirus replication in macrophage-like cell lines. Nature 1979, 282, 509-511.
88. Peiris, J.S.; Gordon, S.; Unkeless, J.C.; Porterfield, J.S. Monoclonal anti-Fc receptor IgG blocks antibody enhancement of viral replication in macrophages. Nature 1981, 289, 189-191.
89. Takeda, A.; Tuazon, C.U.; Ennis, F.A. Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science 1988, 242, 580-583.
90. Robinson, W.E., Jr.; Montefiori, D.C.; Mitchell, W.M. Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. Lancet 1988, 1, 790-794.
91. Li, G.M.; Chiu, C.; Wrammert, J.; McCausland, M.; Andrews, S.F.; Zheng, N.Y.; Lee, J.H.; Huang, M.; Qu, X.; Edupuganti, S.; et al. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc. Natl. Acad. Sci. USA 2012, 109, 9047-9052.
92. Correia, B.E.; Ban, Y.E.; Holmes, M.A.; Xu, H.; Ellingson, K.; Kraft, Z.; Carrico, C.; Boni, E.; Sather, D.N.; Zenobia, C.; et al. Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. Structure 2010, 18, 1116-1126.
93. Ofek, G.; Guenaga, F.J.; Schief, W.R.; Skinner, J.; Baker, D.; Wyatt, R.; Kwong, P.D. Elicitation of structure-specific antibodies by epitope scaffolds. Proc. Natl. Acad. Sci. USA 2010, 107, 17880-17887.
94. McLellan, J.S.; Correia, B.E.; Chen, M.; Yang, Y.; Graham, B.S.; Schief, W.R.; Kwong, P.D. Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus. J. Mol. Biol. 2011, 409, 853-866.
95. Azoitei, M.L.; Correia, B.E.; Ban, Y.E.; Carrico, C.; Kalyuzhniy, O.; Chen, L.; Schroeter, A.; Huang, P.S.; McLellan, J.S.; Kwong, P.D.; et al. Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold. Science 2011, 334, 373-376.
96. Correia, B.E.; Bates, J.T.; Loomis, R.J.; Baneyx, G.; Carrico, C.; Jardine, J.G.; Rupert, P.; Correnti, C.; Kalyuzhniy, O.; Vittal, V.; et al. Proof of principle for epitope-focused vaccine design. Nature 2014, 507, 201-206.
97. Schneemann, A.; Speir, J.A.; Tan, G.S.; Khayat, R.; Ekiert, D.C.; Matsuoka, Y.; Wilson, I.A. A virus-like particle that elicits cross-reactive antibodies to the conserved stem of influenza virus hemagglutinin. J. Virol. 2012, 86, 11686-11697.
98. Belshe, R.B.; Gruber, W.C.; Mendelman, P.M.; Mehta, H.B.; Mahmood, K.; Reisinger, K.; Treanor, J.; Zangwill, K.; Hayden, F.G.; Bernstein, D.I.; et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J. Infect. Dis. 2000, 181, 1133-1137.
99. Bandell, A.; Woo, J.; Coelingh, K. Protective efficacy of live-attenuated influenza vaccine (multivalent, Ann Arbor strain): A literature review addressing interference. Expert Rev. Vaccines 2011, 10, 1131-1141.
100. Karron, R.A.; Talaat, K.; Luke, C.; Callahan, K.; Thumar, B.; DiLorenzo, S.; McAuliffe, J.; Schappell, E.; Suguitan, A.; Mills, K.; et al. Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Vaccine 2009, 27, 4953-4960.
101. Jang, Y.H.; Seong, B.L. Cross-protective immune responses elicited by live attenuated influenza vaccines. Yonsei Med. J. 2013, 54, 271-282.
102. Jang, Y.H.; Seong, B.L. Principles underlying rational design of live attenuated influenza vaccines. Clin. Exp. Vaccine Res. 2012, 1, 35-49.
103. Cox, R.J.; Brokstad, K.A.; Ogra, P. Influenza virus: Immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand. J. Immunol. 2004, 59, 1-15.
104. Jang, Y.H.; Byun, Y.H.; Lee, Y.J.; Lee, Y.H.; Lee, K.H.; Seong, B.L. Cold-adapted pandemic 2009 H1N1 influenza virus live vaccine elicits cross-reactive immune responses against seasonal and H5 influenza A viruses. J. Virol. 2012, 86, 5953-5958.
105. Shi, J.; Wen, Z.; Guo, J.; Zhang, Y.; Deng, G.; Shu, Y.; Wang, D.; Jiang, Y.; Kawaoka, Y.; Bu, Z.; et al. Protective efficacy of an H1N1 cold-adapted live vaccine against the 2009 pandemic H1N1, seasonal H1N1, and H5N1 influenza viruses in mice. Antiviral Res. 2012, 93, 346-353.
106. Talaat, K.R.; Luke, C.J.; Khurana, S.; Manischewitz, J.; King, L.R.; McMahon, B.A.; Karron, R.A.; Lewis, K.D.C.; Qin, J.; Follmann, D.A.; et al. A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response. J. Infect. Dis. 2014, 209, 1860-1869.
107. Suguitan, A.L., Jr.; Cheng, X.; Wang, W.; Wang, S.; Jin, H.; Lu, S. Influenza H5 hemagglutinin DNA primes the antibody response elicited by the live attenuated influenza A/Vietnam/1203/2004 vaccine in ferrets. PLoS One 2011, 6, e21942.
108. Doyle, T.M.; Hashem, A.M.; Li, C.; Van Domselaar, G.; Larocque, L.; Wang, J.; Smith, D.; Cyr, T.; Farnsworth, A.; He, R.; et al. Universal anti-neuraminidase antibody inhibiting all influenza A subtypes. Antiviral Res. 2013, 100, 567-574.
109. Moise, L.; Terry, F.; Ardito, M.; Tassone, R.; Latimer, H.; Boyle, C.; Martin, W.D.; de Groot, A.S. Universal H1N1 influenza vaccine development: Identification of consensus class II hemagglutinin and neuraminidase epitopes derived from strains circulating between 1980 and 2011. Hum. Vaccines Immunother. 2013, 9, 1598-1607.
110. Doyle, T.M.; Li, C.; Bucher, D.J.; Hashem, A.M.; Van Domselaar, G.; Wang, J.; Farnsworth, A.; She, Y.M.; Cyr, T.; He, R.; et al. A monoclonal antibody targeting a highly conserved epitope in influenza B neuraminidase provides protection against drug resistant strains. Biochem. Biophys. Res. Commun. 2013, 441, 226-229.
111. Vincent, A.L.; Ma, W.; Lager, K.M.; Richt, J.A.; Janke, B.H.; Sandbulte, M.R.; Gauger, P.C.; Loving, C.L.; Webby, R.J.; Garcia-Sastre, A. Live attenuated influenza vaccine provides superior protection from heterologous infection in pigs with maternal antibodies without inducing vaccine-associated enhanced respiratory disease. J. Virol. 2012, 86, 10597-10605.
112. Egorov, A.; Brandt, S.; Sereinig, S.; Romanova, J.; Ferko, B.; Katinger, D.; Grassauer, A.; Alexandrova, G.; Katinger, H.; Muster, T. Transfectant influenza A viruses with long deletions in the NS1 protein grow efficiently in Vero cells. J. Virol. 1998, 72, 6437-6441.
113. Stech, J.; Garn, H.; Wegmann, M.; Wagner, R.; Klenk, H.D. A new approach to an influenza live vaccine: Modification of the cleavage site of hemagglutinin. Nat. Med. 2005, 11, 683-689.
114. Jang, Y.H.; Byun, Y.H.; Lee, K.H.; Park, E.S.; Lee, Y.H.; Lee, Y.J.; Lee, J.; Kim, K.H.; Seong, B.L. Host defense mechanism-based rational design of live vaccine. PLoS One 2013, 8, e75043.